Other MLCK1 inhibitors, including myokinasib-II and the MLCK1 membrane recruitment inhibitor divertin have been reported, but while divertin has also been shown to inhibit gut epithelial permeability and disease in animal models of inflammatory bowel disease, no effects on lung inflammation or clinical development activities have been reported (156, 157). Here, MYLK is linked to inflammatory bowel disease.